BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » MaStherCell SA

MaSTherCell SA Enters Belgium Lease to Expand Manufacture of Cell & Gene Therapies

March 26, 2019 By Cade Hildreth (CEO) Leave a Comment

MaSTherCell S.A.’s lease agreement for a 5,700m2 (61,354ft²) facility in Belgium will expands its European manufacturing capacity for late-stage and commercially-approved cell and gene therapy products.

GOSSELIES, BELGIUM – March 26, 2019 – MaSTherCell S.A. a subsidiary of Masthercell Global Inc., a cell and gene therapy-dedicated Contract Development and Manufacturing Organization (CDMO) announces that it has signed a lease agreement for a 5,700m2 (61,354ft²) facility located in Belgium. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell and gene therapy products. The commercial facility is expected to be operational in early 2021.

This new site will significantly expand MaSTherCell’s current European manufacturing capacity. MaSTherCell will continue to use its existing site for both industrialization and early to mid-stage clinical programs.

The facility will include industry 4.0 precepts such as software integration, intelligent equipment and integrated processes with the objective to provide the cell and gene therapy community a lean solution for giving its partners a competitive advantage.

“As a leading CDMO, MaSTherCell has a role to play in solving the current lack of commercial manufacturing capacities in Europe and we believe this facility will be a game changer for market access worldwide,” said Dr. Denis Bedoret, CEO of MaSTherCell SA and President of Masthercell Global. “With this new site, we aim to be the first CDMO in Europe to have a dedicated area for large-scale commercial manufacturing.”

“It was natural for us to set up this state-of-the-art plant in the Gosselies Biopark. Not only will we remain close to our current site and centre of excellence, but also because operating in this world-leading biotechnology cluster will enable us to benefit from a first-class environment in terms of skills, people and know-how.

This new production plant will create several hundred jobs and in addition to being able to count on Belgian expertise to train our teams, being in the heart of Europe will undoubtedly be very attractive for our international recruitment,” said Eric Mathieu, Chief of Operations of MaStherCell SA.

Source: MaStherCell SA (PDF)

To learn about other market competitors to MaStherCell SA, view BioInformant’s “Database of Cell and Gene Therapy CMOs / CDMOs.”

Cell and Gene Therapy CMOs
Up Next: What is an RMAT and Who Has One?

Filed Under: Cell Therapy, Press Releases Tagged With: manufacturing, MaStherCell SA

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.